CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
    2.
    发明申请
    CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION 审中-公开
    包含羟基烷基淀粉和细胞毒素的方法及其制备方法

    公开(公告)号:US20130217871A1

    公开(公告)日:2013-08-22

    申请号:US13809203

    申请日:2011-07-11

    IPC分类号: C08B31/00

    CPC分类号: C08B31/00 A61K47/61

    摘要: The present invention relates to hydroxyalkyl starch conjugates and a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one primary hydroxyl group, wherein the hydroxyalkyl starch is linked via said primary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS′(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold and a molar substitution (MS) in the range of from 0.6 to 1.5.

    摘要翻译: 本发明涉及羟基烷基淀粉共轭物及其制备方法,包含羟烷基淀粉衍生物和细胞毒性剂的羟烷基淀粉缀合物,细胞毒性剂包含至少一个伯羟基,其中羟烷基淀粉通过所述初级 羟基对细胞毒性剂。 根据本发明的缀合物具有根据下式HAS'( - LM)n的结构,其中M是细胞毒性剂的残基,L是连接部分,HAS'是羟烷基淀粉衍生物的残基,以及 n大于或等于1,其中羟烷基淀粉衍生物的平均分子量(MW)高于肾阈值,摩尔取代度(MS)在0.6至1.5的范围内。

    CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
    9.
    发明申请
    CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION 审中-公开
    包含羟基烷基淀粉和细胞毒素的方法及其制备方法

    公开(公告)号:US20140073778A9

    公开(公告)日:2014-03-13

    申请号:US13809074

    申请日:2011-07-11

    IPC分类号: C08B31/10

    摘要: The present invention relates to hydroxyalkyl starch conjugates, a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent and the cytotoxic agent comprising at least one tertiary hydroxyl group, wherein the hydroxyalkyl starch is linked via said tertiary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS′(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

    摘要翻译: 本发明涉及羟烷基淀粉共轭物,其制备方法,包含羟烷基淀粉衍生物和细胞毒性剂的羟烷基淀粉缀合物和包含至少一个叔羟基的细胞毒性剂,其中羟烷基淀粉通过所述第三级 羟基对细胞毒性剂。 根据本发明的缀合物具有根据下式HAS'( - LM)n的结构,其中M是细胞毒性剂的残基,L是连接部分,HAS'是羟烷基淀粉衍生物的残基,以及 n大于或等于1,并且其中羟烷基淀粉衍生物具有高于肾阈值的平均分子量(MW)。

    CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
    10.
    发明申请
    CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION 审中-公开
    包含羟基烷基淀粉和细胞毒素的方法及其制备方法

    公开(公告)号:US20130184454A1

    公开(公告)日:2013-07-18

    申请号:US13809074

    申请日:2011-07-11

    IPC分类号: C08B31/10

    摘要: The present invention relates to hydroxyalkyl starch conjugates, a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent and the cytotoxic agent comprising at least one tertiary hydroxyl group, wherein the hydroxyalkyl starch is linked via said tertiary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS′(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

    摘要翻译: 本发明涉及羟烷基淀粉共轭物,其制备方法,包含羟烷基淀粉衍生物和细胞毒性剂的羟烷基淀粉缀合物和包含至少一个叔羟基的细胞毒性剂,其中羟烷基淀粉通过所述第三级 羟基对细胞毒性剂。 根据本发明的缀合物具有根据下式HAS'( - LM)n的结构,其中M是细胞毒性剂的残基,L是连接部分,HAS'是羟烷基淀粉衍生物的残基,以及 n大于或等于1,并且其中羟烷基淀粉衍生物具有高于肾阈值的平均分子量(MW)。